Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
A phase 3 trial testing Opevesostat in prostate cancer, now recruiting.
Overview
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) is a phase 3 interventional study registered as NCT06136624, led by Merck Sharp & Dohme, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003). Planned enrolment is 1310 participants (estimated). The study started in 2023-12-31 and primary completion is expected in 2028-08-02. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Shares Opevesostat, Merck & Co. (MSD), Prostate cancer and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.